In terms of clinical data from the Betaseron® trial, there was statistically significant evidence that:

• Patients who were antibody positive after 18 months had higher relapse rates than patients who were antibody negative.
• Patients who were antibody positive after 24 months had more enlarging lesions on their MRIs than patients who were antibody negative.

End of Session II. Thank you for participating. Please look for an email announcing Session III: Clinical management and the role of NAbs, in two weeks.

1 2 3 4 5 Your understanding of the disease or condition How you will diagnose patients with this disorder How you will explain the disease or condition to patients and their families None of the above Breaking news in genetics Dementias Epilepsy Mitochondrial disorders Movement disorders Multiple sclerosis Neuromuscular disorders Pediatric disorders

Betaseron is a registered trademark of Berlex Laboratories, Inc.